

"Express Mail" mailing label number _____

Date of Deposit _____

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Printed Name _____

Signature _____

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Dana Rae Benesh

For: 4-(5-AMINOMETHYL)-INDOLE-1-YLMETHYL)-
BENZAMIDE DERIVATIVES AND RELATED
COMPOUNDS AS OPIOID RECEPTOR ANTAGONISTS
FOR THE TREATMENT OF OBESITY

Docket No.: X-16090

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of documents BA, CA and CB for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/John C. Demeter/

John C. Demeter
Attorney for Applicant(s)
Registration No. 30,167
Phone: 317-276-3785

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

FORM PTO 1449 (modified)		Atty. Docket No. X-16090	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		First Applicant Dana Rae Benesh	
		Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 6,794,406	September 21, 2004	Haning, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	BA	WO 03/101963	December 11, 2003	Eli Lilly and Company		
	BB	WO 2004/080968	September 23, 2004	Eli Lilly and Company		
	BC	WO 2004/080996	September 23, 2004	Eli Lilly and Company		
	BD	WO 2004/026305	April 1, 2004	Eli Lilly and Company		
	BE	WO 2005/061442	July 7, 2005	Eli Lilly and Company		
	BF	WO 2005/066164	July 21, 2005	Eli Lilly and Company		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	Yee, et al., "A Novel Series of Selective Leukotriene Antagonists: Exploration and Optimization of the Acidic Region in 1,6-Disubstituted Indoles and Indazoles," J. Med. Chem, Vol. 33, pgs. 2437-2451 (1990)	
	CB	Database CA 'Online,' Chemical Abstracts Service, Rafalski, et al., "Synthesis and biological evaluation of substituted benzimidazoles – potential GPIIb/IIIa receptor antagonists," XP002332455	
	CC		
	CD		

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.